ABSTRACT Aim: Bronchopulmonary dysplasia (BPD) remains the most common respiratory morbidity in immature infants. This review describes the diagnosis of BPD has evolved and summarises the therapeutic approaches that have made it possible to limit the incidence of BPD.
INTRODUCTION
The survival of very premature neonates has significantly improved with advances in perinatal care. These include the prenatal use of corticosteroids (1, 2) , good obstetric practice, such as maternal transfers to perinatal centres with the expertise to handle the severity of the expected prematurity (3), continuous positive airway pressure (4) (5) (6) and better oxygen control from birth (3) . As the study by Fujiwara et al. in 1980 (7) , many studies have evaluated surfactant Abbreviations BPD, Bronchopulmonary dysplasia; CI, Confidence interval; iNO, inhaled nitric oxide; OR, Odds ratio; PMA, Postmenstrual age.
Key notes
The review focuses on bronchopulmonary dysplasia (BPD), describing its evolution and summarising the therapeutic approaches that have made it possible to limit its incidence. It reviews the literature from the first definition of BPD by Northway in 1967 to the surfactant treatment policies that are currently in use. We concluded that ongoing research on surfactant or stem cell therapy may further improve the respiratory prognosis for prematurely born children.
replacement therapy in an attempt to improve lung protection (8) . The early use of surfactant replacement therapy, after continuous positive airway pressure from birth when the infant has spontaneous ventilation, is standard care these days for respiratory distress management (8, 9) . However, the improvements in neonatal survival account for some of the increase in bronchopulmonary dysplasia (BPD) in very premature neonates (10) . The improvement in neonatal survival is not associated with a lower risk of developing severe BPD which contributes to significant long-term morbidity and resource utilisation for the most immature infants (11) (12) (13) (14) .
The aim of this review was to update the perspectives of BPD prevention with new surfactant treatment policies.
The evolution of BPD diagnosis The relative incidence of BPD has fluctuated as the diagnostic criteria have evolved (15) . BPD was initially defined in 1967 by Northway et al. (16) as a radiological and pathological diagnosis in preterm infants who received mechanical ventilation. In 1979, Tooley suggested that a significant predictor of long-term lung disease in preterm infants might be the requirement for oxygen supplementation at 28 days of postnatal age (17) . In 2001, Jobe and Bancalari proposed a new definition of BPD related to developmental pulmonary arrest, inflammation and fibrosis, with three levels of severity defined at 36 weeks of postmenstrual age (PMA) (18) . Poindexter showed that different definitions at 36 weeks of PMA would lead to significant differences in the BPD rate (19) . Later studies by Walsh et al. (20) and Maitre et al. (15) suggested that, although definitions based on the need for supplementary oxygen at 28 days and, or, 36 weeks of PMA, still provide useful reference points, longitudinal observation and the evaluation of respiratory healthcare use up to one year of age provide more meaningful indicators of long-term respiratory morbidity. Finally, the evolution of respiratory support for chronic lung disease challenges the traditional definitions, which did not relate to the same kind of patients (21) .
Physiopathology
Bronchopulmonary dysplasia is a multifactor disease (22) that includes the presence of cellular debris in distal airways (22) , cellular dysfunction of type II pneumocytes (23) , although the intracellular stock of surfactant is only slightly modified (24) , episodes of oedema bursts (18, 20) and increased oxidative stress (25) . Severe BPD has been associated with inflammation (13, 26, 27) , and placentamediated pregnancy complications, such as amnionitis with foetal consequences, have been associated with moderate to severe BPD (28) . Experimental studies and the study by Raymondos et al. (29) have supported a relationship between inflammation and compositional, structural or functional alterations in pulmonary surfactant that would explain the close association between inflammation and BPD. New prevention policies include cytokine modulation (30) . In addition, alterations in compliance and bronchomotor function disorders (31) , as well as mechanical ventilation by itself, may alter surfactant and growth factor expression (32) . Finally, genetic variants may lead to lower concentrations of surfactant-specific proteins in infants prone to developing pulmonary disease in cases where they have associated risk factors. (23) .
Prevention and treatment
Many therapeutic approaches have been proposed, such as postnatal corticosteroid therapy with dexamethasone or betamethasone, but long-term neurodevelopment impairment remains a concern (1, 33) . In a Cochrane systematic review published in 2017, Onland et al. concluded that an optimal dosage or timing of initiation for the prevention of BPD in preterm infants could not be made based on current level of evidence (34) . However, in 2017, Baud et al. suggested that the results of early low-dose hydrocortisone treatment, evaluated in 256 infants born below 28 weeks gestation and compared to 267 controls, might indicate that the rate of survival without BPD at 36 weeks of PMA could be improved. They found an odds ratio of 1.48 and a 95% confidence interval (95% CI) of 1.02-2.16 (p = 0.04) for survival without neurodevelopment impairment at two years of age (35) . Antioxidant treatments were also evaluated, but without any robust conclusions (25, 36) . Current surfactant strategies and their impact on BPD and longterm respiratory outcome have been well described in Polin et al. in a review article (8) . Also, Seger and Soll concluded their Cochrane systematic review of 13 randomised controlled trials, by stating that infants receiving surfactant treatment had a decreased risk of pneumothorax and pulmonary interstitial emphysema, as well as a decreased risk of BPD or death (37) . There are new surfactant administration policies that use a thin catheter, instead of endotracheal intubation, during non-invasive respiratory support (38) and various assisted ventilation strategies that aim to avoid mechanical ventilation and prevent the onset of pulmonary fibrosis (39, 40) . However, when Doyle et al. carried out a longitudinal study of 546 extremely preterm infants followed up to eight years of age over three time periods, they reported that, despite substantial increases in the use of less invasive ventilation after birth, there was no significant decline in BPD and no significant improvement in lung function in childhood over time (41) .
Caffeine therapy, given to 963 infants, with birthweights of 500 to 1250 g during the first 10 days of life to prevent apnoea, significantly lowered the risk of BPD at 36 weeks of PMA when they were compared to 954 comparable infants receiving a placebo (OR 0.63, 95% CI 0.52-0.76, p < 0.001) (42) . Finally, because of the vascular abnormalities associated with BPD (43), inhaled nitric oxide (iNO) has been suggested as an adjunct therapy, either for prevention (44) or for BPD treatment (45, 46) . In the conclusion of their Cochrane systematic review, Barrington et al. stated that iNO could be effective in preventing BPD, but the statistics were not significant, the effect size was likely to be small and the subject required further study (47) . iNO does not have any adverse effects on surfactant (48) , and the combination of iNO together with surfactant administration could be synergistic, although no study has so far found an appropriate protocol with significant results (49) . All these strategies helped to limit the development of BPD to a certain extent, but they were not strongly effective from a clinical point of view, did not lower the risk of developing severe BPD for the most immature infants and they may be related to major long-term side effects (1,2).
New perspectives with surfactant therapy
Two randomised control trials evaluated the impact of repeated curative surfactant administration in infants at high risk of severe BPD (13, 49) . The protocols were different, but produced consistent results. The TOLSURF trial (49) analysed the primary endpoint of survival to 36 weeks without BPD as a dichotomous variable and compared the two treatment groups. Using a two-sided alpha level of 0.05 and a power of 0.80, the authors calculated that a total sample size of 524 would show a 13% absolute improvement that would be considered clinically important. They enrolled 511 infants born below 28 weeks of gestation who required mechanical ventilation at 7-14 days, and all the infants received iNO and either surfactant or sham instillation every one to three days for a maximum of five doses while intubated. Survival without BPD at 36 weeks of PMA was not different between the two groups (31.3% versus 31.7%) (49) . Likewise, in the CURDYS trial (13), the primary outcome was the time to first successful extubation. A difference of 10 days between the groups with regard to mechanical ventilation would have been considered to be clinically significant in a twosided test with an alpha risk of 5% and a power of 90%. A sample size of at least 50 children per group was expected to be sufficient, based on an estimated 20% risk of losing patients to follow-up. Chronic lung disease at 36 weeks of PMA, one year and two years of age were the secondary outcome measure. After randomisation, 118 neonates born at less than 33 weeks of gestation who still required mechanical ventilation on day 14, with more than 0.30 oxygen requirements, received surfactant or air. There was no difference between the control versus surfactant-treated groups with regard to the duration of mechanical ventilation (38.3 AE 18.5 versus 35.7 AE 20.0 days, p = 0.29 respectively) (13) or at 36 weeks of PMA for the combined outcome of severe BPD or death rates (35.6% versus 27.1%; p = 0.32). However, in both studies, the surfactanttreated infants, with (50) or without (13) iNO, had significant reduced respiratory morbidity prior to one year of age (13, 50) . In the TOLSURF trial, less of the 450 infants followed at one year of age received home respiratory support if they had received surfactant than those who had not (35.8% versus 52.9%, p < 0.05) (50) . Likewise, less of the infants treated with surfactant needed rehospitalisation for respiratory problems after discharge (28.3% versus 51.1%; p = 0.03) in 91 of the 96 surviving infants who were followed by the CURDYS trial at one year (13) .
In addition, we present the results of the infants followed up to two years of age in the CURDYS trial (51) . All surviving infants were eligible for that study. After the parents were interviewed, the infants underwent a complete physical examination by certified trained paediatricians who were not aware of the group they had been randomised to. The eligible infants were evaluated at a median age of 25 months and interquartile range (IQR) of 25-27 months. This showed that in 90/96 (94%) of cases the weight and weight z-scores were significantly higher in infants treated with surfactant than controls at a mean (standard deviation) of 10.9 AE 1.7 versus 10.2 AE 1.8 Kg p = 0.034 for weight and À0.51 AE 1.10 versus À0.96 AE 1.19 for the weight z-score (p = 0.025). No significant difference was observed for height, but a positive trend was noted for head circumference (48.5 AE 4.8 versus 47.3 AE 4.9 cm p = 0.07). Infants hospitalised during their first year of life were more likely to be rehospitalised during their second year (OR 4.182, 95% CI 1.478-11.834). The neurodevelopmental scores were similar between the two groups and 93% of the infants walked at 17.4 AE 2.8 versus 18.4 AE 2.8 months (p = 0.110). These data suggest that infants with prolonged mechanical ventilation treated with repeated surfactant in the neonatal period may have a better outcome than controls at two years of age.
Finally, new strategies of treatment using surfactant as a vehicle have showed promising results. After verifying their physical and biochemical properties, Yeh et al. (52) showed that 128 infants treated with a mixture of budesonide and surfactant showed a significant reduction in the risk of BDP at 36 weeks of PMA or death when compared to 134 controls (OR 0.58; 95% CI 0.44-0.77). In a meta-analysis and systematic review, which included the Yeh et al. study, Venkataraman et al. evaluated the effect of the combined use of surfactant and budesonide to prevent BPD (53). They found a significant 43% reduction in the risk of BPD at 36 weeks of PMA in the infants treated with the budesonide and surfactant mixture compared to the controls. (RR 0.57, 95% CI 0.43-0.76). In addition, a 40% reduction was observed in the composite outcome of death or BPD in the budesonide-surfactant group (RR 0.60, 95% CI 0.49-0.74).
These three studies support our awareness of a close relationship between inflammation, functional alterations in pulmonary surfactant leading to lung injury and bronchopulmonary dysplasia. In the CURDYS study (13) , about 90% of the infants presented with late-onset sepsis. This was consistent with the status of the highly vulnerable patients included in this study, where the overall rate of late-onset sepsis for infants below 33 weeks of gestation, ranged from 14% to 24% in the participating centres. Groneck et al. (39) also demonstrated an association between pulmonary inflammation and increased microvascular permeability during BPD development. Paananen et al. (54) studied 131 very premature infants and found that infants with inflammation and high concentrations of inflammatory cytokines in their cord blood faced a high risk of BPD. These studies suggest that repeating surfactant administration, with or without iNO, may modulate surfactant secondary abnormalities. They also suggest that using budesonide mixed with surfactant may deliver an antiinflammatory steroid to the lung and also reduce the alveolar surface tension, which would improve long-term respiratory outcome.
CONCLUSION
Bronchopulmonary dysplasia remains the most common respiratory morbidity in very premature infants. This is despite the many therapeutic approaches that are available, including early surfactant administration, non-invasive respiratory support and the adaptation of gentle mechanical ventilation with rapid extubation. New policies on how to use surfactant show promising results and new perspectives on surfactant therapy, such as the development of enhanced synthetic surfactant and aerosolised or atomised surfactant administration, could further reduce the burden of longterm respiratory sequelae in the most immature infants. We also anticipate a major potential future role for mesenchymal stem cell treatment in reducing the incidence of BPD (55) .
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